Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma

Knop S, Langer C, Engelhardt M, Muegge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Roellig C, Ostermann H, Schaefer-Eckart K, Ringhoffer M, Guenther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC (2017)


Publication Type: Journal article

Publication year: 2017

Journal

DOI: 10.1038/leu.2017.124

Abstract

Leukemia accepted article preview online, 25 April 2017. doi:10.1038/leu.2017.124.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Knop, S., Langer, C., Engelhardt, M., Muegge, L.-O., Reichle, A., Rösler, W.,... Bargou, R.C. (2017). Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma. Leukemia. https://dx.doi.org/10.1038/leu.2017.124

MLA:

Knop, S., et al. "Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma." Leukemia (2017).

BibTeX: Download